4D pharma plc announced the publication in the journal Alimentary Pharmacology & Therapeutics of the Phase II clinical data for LBP Blautix (MRx1234) for the treatment of irritable bowel syndrome. The results highlight the positive effects of Blautix on key regulator-defined clinical symptoms of IBS, altered bowel habits and abdominal pain, both in patients with IBS with predominant constipation (IBS-C) or IBS with predominant diarrhoea (IBS-D). Blautix was well tolerated, with a safety profile comparable to placebo.
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |